While patients with HER2-negative, hormone receptor (HR)-positive breast cancer are often responsive to endocrine therapy at first presentation, acquired resistance leading to relapse, disease progression, and death is common [14]. This evidence concerns the gene ERBB2 and breast carcinoma.